NNOX vs. INMD, BLFS, MDXG, AORT, EYE, ESTA, AXGN, EMBC, IRMD, and BVS
Should you be buying Nano-X Imaging stock or one of its competitors? The main competitors of Nano-X Imaging include InMode (INMD), BioLife Solutions (BLFS), MiMedx Group (MDXG), Artivion (AORT), National Vision (EYE), Establishment Labs (ESTA), AxoGen (AXGN), Embecta (EMBC), Iradimed (IRMD), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.
Nano-X Imaging vs.
Nano-X Imaging (NASDAQ:NNOX) and InMode (NASDAQ:INMD) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
21.5% of Nano-X Imaging shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 7.7% of Nano-X Imaging shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Nano-X Imaging had 6 more articles in the media than InMode. MarketBeat recorded 8 mentions for Nano-X Imaging and 2 mentions for InMode. InMode's average media sentiment score of 0.55 beat Nano-X Imaging's score of 0.29 indicating that InMode is being referred to more favorably in the news media.
InMode received 128 more outperform votes than Nano-X Imaging when rated by MarketBeat users. However, 73.91% of users gave Nano-X Imaging an outperform vote while only 72.97% of users gave InMode an outperform vote.
Nano-X Imaging currently has a consensus target price of $12.00, indicating a potential upside of 135.29%. InMode has a consensus target price of $21.25, indicating a potential upside of 36.39%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, equities analysts plainly believe Nano-X Imaging is more favorable than InMode.
Nano-X Imaging has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.
InMode has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
InMode has a net margin of 45.91% compared to Nano-X Imaging's net margin of -465.38%. InMode's return on equity of 18.25% beat Nano-X Imaging's return on equity.
Summary
InMode beats Nano-X Imaging on 10 of the 17 factors compared between the two stocks.
Get Nano-X Imaging News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNOX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nano-X Imaging Competitors List
Related Companies and Tools
This page (NASDAQ:NNOX) was last updated on 4/24/2025 by MarketBeat.com Staff
Buy NNOX Stock Free NNOX Stock Alerts